Related Experiment Video
Updated: Nov 16, 2025
09:08
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
7.0K
Long non-coding RNA SNHG25 promotes epithelial ovarian cancer progression by up-regulating COMP
Yinglei Liu1,2, Boqun Xu1, Manhua Liu2
1Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Nanjing Medical University, 262 Zhongshan North Road, Nanjing, 210000, China.
Journal of Cancer
|February 22, 2021
Summary
This study reveals that the long non-coding RNA SNHG25 promotes epithelial ovarian cancer (EOC) progression by up-regulating COMP. Downregulating SNHG25 may offer a therapeutic strategy for EOC.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Long non-coding RNAs (lncRNAs) are implicated in cancer development.
- The specific role of SNHG25 in epithelial ovarian cancer (EOC) remains uncharacterized.
Purpose of the Study:
- To investigate the role and molecular mechanisms of SNHG25 in EOC.
- To determine if SNHG25 can serve as a potential biomarker for EOC.
Main Methods:
- Quantitative analysis of SNHG25 expression in EOC tissues versus normal tissues.
- In vitro functional assays (proliferation, migration, invasion, apoptosis) in ovarian cancer cell lines.
- In vivo xenograft tumor growth studies in nude mice.
- High-throughput sequencing and Western blot to assess COMP expression.
Main Results:
- SNHG25 expression is significantly upregulated in EOC tissues.
- High SNHG25 expression enhances ovarian cancer cell proliferation, migration, and invasion while reducing apoptosis.
- SNHG25 downregulation inhibits tumor growth in vivo.
- SNHG25 knockdown leads to decreased expression of COMP mRNA and protein.
Conclusions:
- SNHG25 promotes EOC progression, potentially through the regulation of COMP.
- SNHG25 represents a potential diagnostic and therapeutic target for epithelial ovarian cancer.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
9.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.4K
02:39lncRNA - Long Non-coding RNAs
3.1K
3.1K
01:22MicroRNAs
3.4K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.4K
02:55The Nucleolus
9.8K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
9.8K
03:03mTOR Signaling and Cancer Progression
4.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.1K
02:07Tumor Progression
6.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.8K